These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22685216)

  • 1. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds.
    Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T
    Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
    Nishimuta H; Sato K; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
    Gill KL; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
    Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
    Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.
    Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T
    Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
    Cubitt HE; Houston JB; Galetin A
    Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO; Knights KM; Houston JB; Mackenzie PI
    Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
    Cubitt HE; Houston JB; Galetin A
    Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells.
    Zhang H; Tolonen A; Rousu T; Hirvonen J; Finel M
    Drug Metab Dispos; 2011 Mar; 39(3):456-64. PubMed ID: 21098645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
    Miners JO; Mackenzie PI; Knights KM
    Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
    Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
    Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
    Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
    Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs.
    Li T; Zheng Y; Fu F; Ji H; Chen X; Zhao Y; Zhao D; Li N; Zhang L
    Xenobiotica; 2011 Jul; 41(7):530-7. PubMed ID: 21524190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay.
    Di Marco A; D'Antoni M; Attaccalite S; Carotenuto P; Laufer R
    Drug Metab Dispos; 2005 Jun; 33(6):812-9. PubMed ID: 15788539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
    Gaganis P; Miners JO; Knights KM
    Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
    Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
    Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.